Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05288751 · ClinicalTrials.gov registry record · NA

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

A NA study of Opioid Use Disorder and Stimulant Use Disorder, sponsored by University of Minnesota.

Active
Registry status
NA
Development phase
56
Enrollment target
1
Study location

NCT05288751: Active NA study of Opioid Use Disorder and Stimulant Use Disorder, sponsored by University of Minnesota.

NCT05288751 is a NA study of Opioid Use Disorder and Stimulant Use Disorder that is active but no longer recruiting, run by University of Minnesota. The registered enrollment target is 56 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05288751, a NA study of Opioid Use Disorder and Stimulant Use Disorder, is active but no longer recruiting, sponsored by University of Minnesota.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

Primary Outcome

Number of completed clinical visits per patient during the CM program.

Interventions

  • BEHAVIORAL Contingency Management

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2022-06-15
Est. Completion 2026-08-31
Phase NA
University of Minnesota

966 total trials

What the registry record for NCT05288751 still lists

NCT05288751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Contingency Management is the first listed.

NCT05288751 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05288751 about?

NCT05288751 is a clinical study titled "Contingency Management for Opioid and Stimulant Use Disorders in Primary Care". Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit...

What is the current status of trial NCT05288751?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2022-06-15. Estimated completion is 2026-08-31.

What conditions does trial NCT05288751 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Stimulant Use Disorder.

What interventions are being tested in trial NCT05288751?

The interventions under investigation include: Contingency Management (BEHAVIORAL).

Who is sponsoring clinical trial NCT05288751?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05288751 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05288751's enrollment target sits among peer trials

56 168th of 257 higher than 90 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05288751, the US trial registry maintained by the National Library of Medicine. NCT05288751 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.